Cloudflare: The New Traffic Cop Of The Internet
Cloudflare is uniquely positioned at the intersection of internet infrastructure and AI, with its Workers platform and MCP protocol driving new developer and enterprise adoption. The shift toward an AI-driven internet benefits Cloudflare, as its edge network and serverless offerings enable secure, scalable, and low-latency AI application deployment. Financials show strong growth: 26% YoY revenue increase, expanding large customer base, and high-margin incremental revenue from AI services with minimal additional capex.
Cloudflare (NET) Registers a Bigger Fall Than the Market: Important Facts to Note
In the most recent trading session, Cloudflare (NET) closed at $184.95, indicating a -5.56% shift from the previous trading day.
Cloudflare launches tool to help publishers charge AI firms for content use
Cloudflare has unveiled new software that lets websites block unauthorised AI crawlers and set prices for access, in a bid to help content creators monetise their work amid declining referral traffic. The tool, announced on Tuesday, introduces a “pay per crawl” model allowing site owners to decide whether and how artificial intelligence models can use their material.
Web giant Cloudflare to block AI bots from scraping content by default
Starting Tuesday, every new web domain that signs up to Cloudflare will be asked if they want to allow or block AI crawlers. At least 16% of the world's internet traffic gets routed through Cloudflare, one of the world's largest content delivery networks.
Cloudflare Introduces Blocking of A.I. Scrapers By Default
The tech company's customers can automatically block A.I. companies from exploiting their websites, it said, as it moves to protect original content online.
Cybersecurity Stock Ready to Extend Run Higher
Cloudflare Inc (NYSE:NET) shares are up 0.7% to trade at $195.32, and earlier surged to a more than three-year high of $196.20, with support from their 20-day moving average.
Why Cloudflare Could Be The Best Pure-Play On Edge Compute
Cloudflare's evolution into a 'connectivity cloud' creates a unique, programmable global edge network, driving durable growth beyond its CDN origins. The company's integrated platform leverages edge GPUs for AI inference, Zero Trust security, and developer adoption, compounding network effects and switching costs. Financials show robust 27% revenue growth, expanding cash flow margins, and disciplined capex, supporting management's long-term model and premium valuation.
Cloudflare stock price forecast: eying ATH after flipping key resistance
Cloudflare stock price has gone parabolic and crossed an important resistance level as demand for its services and its market share soared. NET jumped to a high of $195, its highest level since November 2021, and 410% above its lowest point in 2022, giving it a market cap of over $60 billion.
Cloudflare, Inc. (NET) is Attracting Investor Attention: Here is What You Should Know
Cloudflare (NET) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Cloudflare Expands AI Tools: Will Revenue Growth Follow?
NET sees AI-driven usage surge with rise in inference requests and growing enterprise adoption boosting prospects.
Why Cloudflare (NET) Outpaced the Stock Market Today
In the closing of the recent trading day, Cloudflare (NET) stood at $183.87, denoting a +2.55% move from the preceding trading day.
![Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial](https://images.financialmodelingprep.com/news/perspective-therapeutics-commences-recruitment-for-212pbvmtnet-in-the-third-20250621.jpg)
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT).
